A new single-shot rabies vaccine is in it's early trial phase, but has already "performed even better" than expected in protecting against the disease, early research suggests.
Trial results, which are published in the Lancet Microbe, have also indicated that the inoculation is safe for administration.
The new jab aims to address some of the main problems with existing rabies vaccines, which are expensive and require multiple doses. Researchers say it could help prevent thousands of deaths from the disease every year.
